CD38 and plasma cell myeloma: The most advanced of these developmental partnerships is with daratumumab (DARZALEX®; Janssen), the first approved monoclonal antibody for the treatment of multiple myeloma targeting CD38, an antigen highly expressed on multiple myeloma cells.